Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models
- PMID: 22072808
- DOI: 10.1158/1535-7163.MCT-11-0721
Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models
Comment on
-
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. doi: 10.1158/1535-7163.MCT-07-0365. Mol Cancer Ther. 2007. PMID: 18089725
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
